Executive Leadership
Operating leadership for organizations building biotechnology companies around complex science.
- Executive direction
- Strategic operations
- Organizational clarity
- Company-building priorities
Attenuated Technologies
Building biotechnology companies through executive operating work.
Attenuated Technologies is an independent biotechnology operating practice founded and led by Michael Churchill, Ph.D.
The practice provides a platform for selected executive appointments, strategic engagements, company-building opportunities, and future advisory roles.
Founder & Principal
Michael Churchill is Founder and Principal of Attenuated Technologies.
The practice provides continuity across executive appointments, leadership engagements, and company-building activities rather than presenting a chronology of employers.
Its work sits at the intersection of science, technology, artificial intelligence, execution, organizational design, and company building.
Core Capabilities
Organizational Design
Building the structures, interfaces, governance, and decision systems required to execute complex scientific programs.
- Cross-functional operating models
- Team design
- Accountability
- Decision-making systems
AI-Native Biotechnology
Applying artificial intelligence as an organizational capability across scientific workflows, knowledge systems, and decision-making.
- AI-enabled scientific workflows
- Research automation
- Internal knowledge systems
- Organizational leverage
Translational Science and Precision Medicine
Connecting scientific hypotheses, biomarkers, clinical evidence, development risk, and execution.
- Biomarkers
- Translational strategy
- Clinical evidence planning
- Precision medicine
Company Formation and Growth
Translating technical potential into a coherent company thesis, development plan, and organization.
- Company formation
- Strategic differentiation
- Product thinking
- Corporate growth
Strategic Operations
Integrating scientific, technical, clinical, and business decisions as organizations move from intent to execution.
- Program prioritization
- Operating cadence
- Risk framing
- Cross-functional execution
Practice Partners
Founders
Founders building a company thesis, platform strategy, initial programs, organization, or financing narrative.
Executive Teams
Leaders aligning scientific strategy, organizational capability, and execution.
Investors and Strategic Partners
Organizations seeking scientific, technical, translational, or operating perspective.
Future Advisory Opportunities
Organizations seeking independent scientific judgment, company-building experience, or strategic and organizational perspective.
Operating Modes
Advisory is one operating mode within a broader executive practice. The appropriate mode follows the organization, decision, and stage of work.
Executive Leadership
Executive appointments focused on building organizations and advancing company priorities.
Fractional Executive Appointments
Focused executive leadership during company formation, transition, growth, financing, program advancement, or organizational change.
Strategic Advisory
Independent perspective on consequential scientific, organizational, and company-building decisions.
Future Board and Advisory Roles
Exploratory opportunities where scientific judgment, company-building experience, and emerging-technology perspective are relevant.
Venture Support
Scientific, translational, technical, and operating perspective for biotechnology opportunities.
Company Formation
Work to define a company thesis, platform strategy, initial organization, and development priorities.
AI-Native Organizational Transformation
Practical application of artificial intelligence to scientific workflows, operating models, and organizational leverage.
How the Practice Works
The practice begins with the organization and the decision that matters most.
Start With the Decision
Define the consequential decision before creating activity for its own sake.
Integrate Science and Business
Evaluate scientific choices alongside company strategy, capital requirements, partnerships, timelines, and organizational design.
Create Clarity
Identify assumptions, risks, dependencies, tradeoffs, and decision points so complex work becomes actionable.
Stay Close to Execution
Translate strategy into ownership, sequencing, milestones, operating plans, and decisions.
Maintain Intellectual Honesty
Use direct communication, evidence-based reasoning, and a willingness to challenge assumptions.
Build Capability
Strengthen the organization's ability to make better decisions and execute effectively.
Representative Engagements
The practice is grounded in operating experience across company formation, synthetic biology, AI-native diagnostics, translational medicine, first-in-human development, organizational design, commercialization, and acquisition.
MultiOmics
MultiOmics is an AI-native precision-diagnostics company focused on early breast-cancer detection.
- Michael's role
- Interim CSO/CBO through Attenuated Technologies. Michael leads scientific development, operating coordination, corporate strategy, business-development support, and AI strategy.
- Outcome
- Selected for the 2025 C10/LabCentral AI-BioHub cohort. Michael created the application and pitch materials used during the program.
Brahma Therapeutics
Brahma Therapeutics was formed around a de novo peptide-engineering platform and the opportunity to translate foundational academic technologies into a biotechnology company.
- Michael's role
- Founder & Chief Scientist. Michael negotiated foundational licenses, defined the platform and development strategy, and built the scientific operation from concept through proof of concept.
- Outcome
- Brahma was positioned for and reached a strategic acquisition outcome in May 2023.
CREATE Medicines / Myeloid Therapeutics
CREATE Medicines, formerly Myeloid Therapeutics, is a clinical-stage biotechnology company advancing in vivo CAR programs through first-in-human development.
- Michael's role
- Senior Director, Translational Science. Michael led biomarker strategy and translational execution for MT302 and directed cross-functional startup of multinational Phase I program MT303.
- Outcome
- Michael's translational work supported full enrollment of MT302 in under 12 months. MT303 expanded the clinical pipeline and international operating footprint.
SEngine Precision Medicine
SEngine developed a functional precision-oncology platform intended to move from assay development into a CLIA-certified clinical diagnostic service.
- Michael's role
- Lead Scientist, then Principal Scientist. Michael built the CLIA-certified P.A.R.I.S. test and later supported its physician-facing clinical implementation and broader company development.
- Outcome
- Michael developed personalized drug panels for more than 100 cancer patients and supported an approximately $9 million financing through financial analysis, valuation work, diligence materials, and company presentations. The CEO led the financing.
Board Participation and Venture Support
Attenuated Technologies welcomes future conversations where independent scientific judgment, company-building experience, and an understanding of emerging technologies can improve strategic decision-making.
The practice does not imply existing board credentials or board service beyond what is separately documented.
Appropriate Conversations
Relevant conversations may include:
- Executive appointments
- Fractional leadership
- Defining a biotechnology company strategy
- Evaluating a scientific platform
- Designing an organization around complex science
- Preparing a program for clinical development
- Applying artificial intelligence within biotechnology R&D
- Supporting venture diligence
- Exploring future advisory opportunities
- Company formation
Start with the organization that needs to be built.
For executive appointments, selected strategic engagements, company formation, future advisory opportunities, or speaking, contact Michael directly.